Trials / Completed
CompletedNCT06198686
An Evaluation of The Absolute Bioavailability of TH104
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Tharimmune Inc · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a single-dose, single-center, open-label, randomized, 2-way crossover study (2 treatments, 2 periods and 2 sequences) of a buccal formulation of Nalmefene 16 mg and a 1 mg intravenous dose of nalmefene injection, with a least 7 days washout period between doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nalmefene | Opioid antagonist |
Timeline
- Start date
- 2024-01-26
- Primary completion
- 2024-02-11
- Completion
- 2024-11-06
- First posted
- 2024-01-10
- Last updated
- 2025-04-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06198686. Inclusion in this directory is not an endorsement.